Wong MOM, et al. - Researchers conducted this retrospective case series to identify the 2-year effectiveness and safety of oral valganciclovir in cytomegalovirus (CMV) anterior uveitis (AU) with uncontrolled intraocular pressure (IOP). One eye from each of 17 immunocompetent PCR-proven patients with CMV AU who received a single course of oral valganciclovir for 20–148 days for medically uncontrolled IOP during 2008–2018 have been identified. According to results, median baseline IOP and IOP-lowering medication were 27.0 mmHg and 4.0, respectively. No serious medication-related adverse event has been identified. Reduced monocyte count and deranged renal function/electrolytes were common side effects. The authors discovered that >1/3 of the patients in CMV AU with uncontrolled IOP avoided glaucoma surgery over 2 years with a course of oral valganciclovir.